2. >
  3. Investors
  4. >
  5. Regulated Information
  6. >
  7. Press Releases – Reg...

PRESS RELEASES

Found 274 Results
Page 3 of 28

Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States


This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]

Tags:

09/03/2020

Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer


DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]

Tags:

08/27/2020

Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility


Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

07/29/2020

Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux


July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

Tags:

07/03/2020

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties


Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

06/25/2020

New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020


Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]

Tags:

06/22/2020

Onxeo: report on the Extraordinary General Meeting of June 19, 2020


Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

06/19/2020

Onxeo offre 10,7% de son capital à Invus – Biotech Finances


(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]

Tags:

06/15/2020

BFM Business Intégrale Bourse : Onxeo, Company of the Day


  Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]

Tags: ,

06/10/2020

Page 3 of 28
Onxeo: report on the Extraordinary General Meeting of June 19, 2020
19-06-2020
Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder
09-06-2020
Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions
29-05-2020
Onxeo Announces Approval of the REVocan Study By Regulatory Authorities
29-05-2020
Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation
27-05-2020
Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi
19-05-2020
Onxeo’s Joint General Meeting in camera on May 29, 2020: availability of preparatory documents and live webcast login information
07-05-2020
Publication of the 2019 Universal Registration Document
27-04-2020
Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update
17-04-2020
Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC
06-04-2020